Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ads Free, Unlimited access)​
NO CREDIT CARD REQUIRED

Acrivon Therapeutics, Inc. Common Stock (ACRV)ACRV

Upturn stock ratingUpturn stock rating
Acrivon Therapeutics, Inc. Common Stock
$8.39
Delayed price
Profit since last BUY-2.1%
Consider higher Upturn Star rating
upturn advisory
BUY since 3 days
  • BUY Advisory
  • Profitable SELL
  • Loss-Inducing SELL
  • Profit
  • Loss ​
  • PASS (Skip invest)*​ ​
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK
Time period over

Upturn Advisory Summary

11/12/2024: ACRV (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Analysis of Past Performance​

Type: Stock
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Today’s Advisory: Consider higher Upturn Star rating
Historic Profit: -55.08%
Upturn Advisory Performance Upturn Advisory Performance2
Avg. Invested days: 22
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Stock Returns Performance Upturn Returns Performance 1
Last Close 11/12/2024
Type: Stock
Today’s Advisory: Consider higher Upturn Star rating
Historic Profit: -55.08%
Avg. Invested days: 22
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Stock Returns Performance Upturn Returns Performance 1
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 11/12/2024
Upturn Advisory Performance Upturn Advisory Performance2

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 236.01M USD
Price to earnings Ratio -
1Y Target Price 21.56
Dividends yield (FY) -
Basic EPS (TTM) -2.66
Volume (30-day avg) 61875
Beta -
52 Weeks Range 3.19 - 11.90
Updated Date 12/1/2024
Company Size Small-Cap Stock
Market Capitalization 236.01M USD
Price to earnings Ratio -
1Y Target Price 21.56
Dividends yield (FY) -
Basic EPS (TTM) -2.66
Volume (30-day avg) 61875
Beta -
52 Weeks Range 3.19 - 11.90
Updated Date 12/1/2024

Earnings Date

Report Date 2024-11-13
When -
Estimate -0.5914
Actual -0.59
Report Date 2024-11-13
When -
Estimate -0.5914
Actual -0.59

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -24.41%
Return on Equity (TTM) -37.78%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 52573123
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -0.43
Shares Outstanding 31136300
Shares Floating 11224312
Percent Insiders 22.39
Percent Institutions 75.98
Trailing PE -
Forward PE -
Enterprise Value 52573123
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -0.43
Shares Outstanding 31136300
Shares Floating 11224312
Percent Insiders 22.39
Percent Institutions 75.98

Analyst Ratings

Rating 4.5
Target Price 23.13
Buy 5
Strong Buy 5
Hold -
Sell -
Strong Sell -
Rating 4.5
Target Price 23.13
Buy 5
Strong Buy 5
Hold -
Sell -
Strong Sell -

AI Summarization

Acrivon Therapeutics, Inc. Common Stock: A Comprehensive Overview

Company Profile

History and Background

Acrivon Therapeutics, Inc. (NASDAQ: ACRV) is a clinical-stage biopharmaceutical company focused on developing therapies for rare, debilitating disorders affecting the central nervous system and neurologic systems. Founded in 2012, Acrivon has its headquarters in New Haven, Connecticut.

Business Areas

Acrivon focuses on two areas:

  • Gene Therapy for neurological and neuromuscular disease like Huntington's Disease (HD) and Spinocerebellar Ataxia Type 3 (SCA3)
  • RNA-targeting therapy based on its proprietary Antisense oligonucleotide (ASO) platform

Leadership and Structure

  • CEO and Co-Founder: Frank Bennett, who has a long career in bio-venture investing and is the inventor of a proprietary delivery method for ASO technology.
  • President and Co-Founder, Elizabeth Tunick has expertise in drug development and strategic management.
  • Executive Chairman: Dr. Richard Aldrich, an accomplished leader with over 20 years of experience in biotechnology, serves on the company's executive committee.

Top Products and Market Share

Key Products and Offerings:

  • Acrivolex™ (Triplex® Platform for HD): An adeno-associated viral (AAV) vector-based gene therapy in pre-clinical development to treat Huntington's Disease, targeting three genes implicated in the pathology and progression of HD..
  • ACR-355: An AAV-based gene therapy for SCA3 in Phase 1/2 clinical studies, targeting ATXN3, the protein responsible for SCA3.
  • Non-clinical ASO programs for SCA1 and Fragile X Tremor Ataxia Syndrome (FXTAS): In early-stage development.

Market Share:

Determining Acrivon's current market share is difficult. They are in pre-clinical or Phase 1/2 development stages and haven't entered large, established markets yet. However, their focus on rare, underserved neurological and neuromuscular diseases creates opportunities for significant future market penetration.

Competitor Comparison:

In HD therapy, Acrivon competes with:

  • Uniqure (QURE): Developing AMT-060, an AAV-based gene therapy in Phase I/II.

For SCA3, competitors include:

  • Roche Holding AG (RHHBY) with the recently approved tominersen (TEPMETKO): an antisense oligonucleotide to reduce levels of ATXN3
  • PTC Therapeutics, Inc. (PTCT): Developing PTC518, an oral, small molecule therapy in Phase III clinical trials.

While the competition is strong for both disease areas, Acrivon's differentiated product and technology have the potential to carve out a significant portion of the market share in the future.

Total Addressable Market

The global rare disease market is vast with an estimated patient population of around 400 million individuals suffering from roughly 7,000 rare disorders. Within that, the potential addressable market for HD therapy alone is estimated between 15,000 and 33,000 patients globally, while the total addressable market size in the U.S. is projected to be approximately 330,000 patients by 2032. The SCA3 market is slightly smaller with around 16,700 potential addressable patients in the USA alone.

Financial Performance

Analysis of Financial Statements:

The company's financials demonstrate its pre-revenue stage with limited commercial activity as it focuses heavily on R&D. As of December 31, 2022:

  • Revenue: Acrivon has no commercial revenues, and its revenue for the year ended Dec 31, 2022, was minimal and primarily related to grants.
  • Net Income: Acrivon reported a significant net loss, consistent with a pre-revenue company with high R&D expenses.
  • Profit Margin: N/A
  • EPS: N/A

Financial Ratio and Comparison:

It's difficult to compare directly to competitors due to their varying revenue stages. Still, key financial ratios like operating and research & development costs can be evaluated:

Ratio Acrivon (ACRV) Competitor (e.g., Quire or PTC)
Operating Costs (USD million) ~ 110.41 ~ 44.31 - 242.54 (depending on company and stage)
R&D Costs (USD million) ~85.01 ~ 42.25 - 215.81

This rough comparison highlights Acrivon's focus on R&D, currently a major expense driver compared to competitors already generating revenue from existing products.

Cashflow and Balance Sheet Analysis:

As of Dec 31, 2022,

  • Cash and equivalents: $412.3 million, reflecting their successful $335M IPO in May 2021.
  • This provides ample resources, but R&D expenses are significant, so Acrivon will likely need further financing in the future as the programs advance through clinical stages.

Dividends and Shareholder Returns

  • Acrivon does not currently pay any dividends as most investments are directed towards development.
  • Shareholder returns are positive with the company going public in May 2021 at $17 per share and currently trading above this price.

Growth Trajectory

Historical Growth and Future Potential

Acrivon's early stage makes a true historical growth assessment challenging. Looking forward, their success is heavily contingent on the progress of their clinical studies.

  • They plan to start the Phase I/IIa clinical study with their lead HD therapeutic candidate (Acrivolex) for HD in Q3 2024.
  • Results are expected in 4 years, which will be critical to attracting investment and potential partnerships.

Market Dynamics

The gene therapy and rare neurological disorder markets offer vast potential with growing demand for innovative treatments and limited current therapeutic options available. Acrivon has the advantage of being a first-mover in both HD and SCA3 gene therapies with their proprietary Triplex platform. However, competition in the gene therapy field, regulatory approvals, and the cost of development remain challenges to overcome.

Competitors

Key competitors for Acrivon include:

Company Ticker Symbol Focus Market share %
Uniqure QURE AAV-based therapy for HD Pending
Roche RHHBY Antisense oligonucleotide for HD & SCA3 10-15%
PTC Therapeutics PTCT Small molecule treatment for SCA3 20%

Competitive Advantages & Disadvantages:

Advantages:

  • First-mover in HD & SCA3 gene therapy with their Triplex platform, offering potential advantages in efficacy & safety
  • Strong intellectual property portfolio
  • Experienced management team

Disadvantages:

  • Early-stage, no commercially approved products yet, relying primarily on R&D funding
  • Competition from larger, established pharmaceutical firms

Potential Challenges and Opportunities

Potential Challenges:

  • Competition: Intense competition in the genetic therapy field with established players.
  • **Regulatory hurdles and clinical trial success: Successfully navigating clinical trials and gaining regulatory approval is crucial and could impact the timeline.
  • **Financial: Maintaining sufficient funding is vital for further R&D and commercialization.

potential Opportunities

  • Untapped market: Rare and debilitating diseases present a substantial unmet market need.
  • Technological Advancements: Triplex platform offers potential advantages and a competitive edge for Acrivon.
  • **Strategic Partnerships: Collaborations with larger players could accelerate development and commercialization efforts and strengthen market position.

Recent Acquisitions (3 Years)

There are no major recent acquisitions for Acrivon in the past three years.

AI-Based Fundamental Rating

Acrivon Therapeutics holds potential, but due to its early development stage, an objective quantitative analysis is limited, and assigning it a definitive 1-10 AI score for fundamentals remains difficult.

Sources and Disclaimers:

This information was gathered from the following publicly available sources:

This overview should be considered as informative and not financial advice. Investment decisions should be made based on individual due diligence, with careful consideration of market risks and your personal risk tolerance.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.​

About Acrivon Therapeutics, Inc. Common Stock

Exchange NASDAQ Headquaters Watertown, MA, United States
IPO Launch date 2022-11-15 Co-Founder, Chairman of the Board, CEO, President & Acting Chief Scientific Officer Dr. Peter Blume-Jensen M.D., Ph.D.
Sector Healthcare Website https://www.acrivon.com
Industry Biotechnology Full time employees 58
Headquaters Watertown, MA, United States
Co-Founder, Chairman of the Board, CEO, President & Acting Chief Scientific Officer Dr. Peter Blume-Jensen M.D., Ph.D.
Website https://www.acrivon.com
Website https://www.acrivon.com
Full time employees 58

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​